Loading clinical trials...
Loading clinical trials...
Phase 1 Clinical Trial of Intravesical Adoptive Cell Therapy {ACT) With Tumor Infiltrating Lymphocytes (TIL) for Patients With BCG Exposed High Grade Non-Muscle Invasive Bladder Cancer (NMIBC)
Conditions
Interventions
Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)
Locations
1
United States
Moffitt Cancer Center
Tampa, Florida, United States
Start Date
August 10, 2023
Primary Completion Date
October 10, 2025
Completion Date
January 1, 2027
Last Updated
December 4, 2025
NCT07061964
NCT05987241
NCT06349642
NCT07452432
NCT06668493
NCT06809140
Lead Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions